secwatch.observer — SEC 8-K summary
======================================

Issuer:     Metagenomi Therapeutics, Inc. (MGX)
CIK:        0001785279
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001193125-26-093943
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Metagenomi reports $160.8M cash, MGX-001 on track for IND in 4Q 2026
--------------------------------------------------------------------

- Cash, equivalents and marketable securities $160.8M as of Dec 31, 2025; runway through 4Q 2027.
- R&D expenses $94.4M in FY2025 (down 13.6% from FY2024); G&A $26.8M (down 16.3% from $32.0M).
- MGX-001 hemophilia A pre-IND meeting completed; IND filing expected 4Q 2026, clinical trials in 2027.
- Preclinical NHP data showed curative FVIII levels; in vivo proof-of-concept for Antithrombin deficiency also achieved.
- Corporate name changed to Metagenomi Therapeutics; Ionis collaboration advancing APOC3 target in cardiometabolic indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785279/000119312526093943/0001193125-26-093943-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785279/000119312526093943/mgx-20260305.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-093943

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer